GAMIDA CELL LTD.

(GMDA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Needham Adjusts Price Target on Gamida Cell to $12 from $14, Keeps Buy Rating

11/16/2021 | 11:41am EDT


© MT Newswires 2021
All news about GAMIDA CELL LTD.
05/17Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences..
BU
05/12GAMIDA CELL LTD. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
05/10TRANSCRIPT : Gamida Cell Ltd., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
BU
05/05Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK)..
BU
05/05Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK)..
CI
05/03Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
BU
04/27Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study..
BU
04/27Gamida Cell Ltd. Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 ..
CI
More news
Analyst Recommendations on GAMIDA CELL LTD.
More recommendations
Financials (USD)
Sales 2022 1,55 M - -
Net income 2022 -77,2 M - -
Net Debt 2022 62,0 M - -
P/E ratio 2022 -1,81x
Yield 2022 -
Capitalization 131 M 131 M -
EV / Sales 2022 125x
Capi. / Sales 2023 3,88x
Nbr of Employees 167
Free-Float 69,8%
Chart GAMIDA CELL LTD.
Duration : Period :
Gamida Cell Ltd. Technical Analysis Chart | GMDA | IL0011552663 | MarketScreener
Technical analysis trends GAMIDA CELL LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 2,19 $
Average target price 13,83 $
Spread / Average Target 532%
EPS Revisions
Managers and Directors
Julian Adams Chief Executive Officer & Director
Shai Lankry Chief Financial Officer
Robert I. Blum Chairman
Ronit Simantov Chief Medical & Scientific Officer
Yona Geffen Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
GAMIDA CELL LTD.-13.78%131
GILEAD SCIENCES, INC.-12.33%79 850
REGENERON PHARMACEUTICALS, INC.7.98%73 473
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
BIONTECH SE-36.69%39 666